ArticleClinical rheumatology2017
Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Article in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Guideline
- Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.Rheumatology (Oxford, England) · 2022Trial
- Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.Annals of the rheumatic diseases · 2021Trial
- Analysis of CCR9, CXCR5 and ICOS in Circulating Follicular Helper T Cell-like Populations in Sjögren's Disease.International journal of molecular sciences · 2026Article
- Is high IgG level associated with disease activity and organ damage in patients with Sjögren's syndrome? A 3-year follow-up cohort study.Clinical and experimental medicine · 2025Article
- Hydroxychloroquine: A double‑edged sword (Review).Molecular medicine reports · 2025Review
- Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Article
- A Review of the Impact of Sjögren's Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Laboratory features and pharmacological management of early and late-onset primary Sjögren's syndrome.Rheumatology international · 2024Article
- Deciphering the immunological interactions: targeting preeclampsia with Hydroxychloroquine's biological mechanisms.Frontiers in pharmacology · 2024Review
- Association of Inflammatory Cytokine Levels with Extra Glandular Manifestations, Fatigue, and Disease Activity in Primary Sjögren's Syndrome in Saudi Patients: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2023Article
- Preeclampsia and the Antiphospholipid Syndrome.Biomedicines · 2023Review
- The Impact of Hydroxychloroquine on Primary Feto-Placental Endothelial Cells from Healthy and Early-Onset Preeclamptic Placentas.International journal of molecular sciences · 2023Article
- Osteoarthritis or arthritis? Toward understanding of primary Sjögren's syndrome patients with arthralgia.Journal of orthopaedic surgery and research · 2023Article
- Clinical features and risk factors of Raynaud's phenomenon in primary Sjögren's syndrome.Clinical rheumatology · 2021Article
- The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2021Review
- Hydroxychloroquine in rheumatic autoimmune disorders and beyond.EMBO molecular medicine · 2020Review
- The effect of pilocarpine on dental caries in patients with primary Sjögren's syndrome: a database prospective cohort study.Arthritis research & therapy · 2019Article
- Managing fatigue in patients with primary Sjögren's syndrome: challenges and solutions.Open access rheumatology : research and reviews · 2019Review
- Advances in the diagnosis and treatment of Sjogren's syndrome.Clinical rheumatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of hydroxychloroquine (HCQ) in Primary Sjögren's Syndrome (pSS) has been assessed in different studies over the last years, with conflicting results regarding its efficacy in sicca syndrome and extraglandular manifestations (EGM). The goal of this study was to compare the incidence rate of EGM in pSS patients with and without HCQ therapy.We performed a multicenter retrospective study, including patients with pSS (European classification criteria) with at least 1 year of follow-up. Subjects with concomitant fibromyalgia, autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis were excluded. Demographics and pSS characteristics were recorded. The EGM were defined by EULAR-SS disease activity index (ESSDAI). Patients were divided into two groups according to their use or not of HCQ therapy. We evaluated the use of HCQ and its relationship to EGM. HCQ therapy was defined as the continuous use of the drug for at least 3 months. A descriptive analysis of demographics and pSS characteristics was performed. We compared the incidence of EGM between groups defined by HCQ therapy using chi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.